Status:
COMPLETED
The Effect of Levetiracetam on Lipid Profile in Children
Lead Sponsor:
Ege University
Conditions:
Epilepsy
Child, Only
Eligibility:
All Genders
1-18 years
Brief Summary
Levetiracetam is a widely prescribed antiseizure medication in epileptic children due to an estimated better safety profile and easy accessibility. There is limited and contradicting data about the ef...
Detailed Description
A total of 37 pediatric epileptic patients (children = 16, adolescents = 21) and 54 healthy control (children = 17, adolescents = 37) were enrolled to the study. Participants admitted to the pediatric...
Eligibility Criteria
Inclusion
- Must be aged between 4 and 17 years
- Must be diagnosed with epilepsy with at least two focal seizures within a year
- Must be treated with levetiracetam monotherapy for at least 12 months.
Exclusion
- other medical conditions requiring continuous medication
- abnormal thyroid function
- progressive neurologic conditions
- abnormal nutritional status (malnutrition, over-weight or obese)
- epilepsy requiring poly-therapy
- genetic diseases causing unbalanced laboratory and hormone profile
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT05276271
Start Date
October 1 2020
End Date
October 31 2021
Last Update
March 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ataturk City Hospital
Altınoluk, Balikesi̇r, Turkey (Türkiye), 10100